Precision BioSciences, Inc. announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B during a poster presentation at the European Association for Study of the Liver Congress 2024 being held June 5-8, 2024 in Milan, Italy.
